Amgen Inc (AMGN) stock
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3026% above fair value
$462.32−3.35 (-0.72%)
Close on Nov 16, 2026Market cap $249.95BP/E 26.8Yield 2.09%
Amgen total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Amgen's total debt was $54.01B at Sep 30, 2026. For fiscal 2025 it was $54.60B, down 9.1% from the year before. Over ten years it grew 5.7% a year on average. The highest annual figure on record is $64.61B in fiscal 2023.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.60B | -9.1% |
| FY2024 | Dec 31, 2024 | $60.10B | -7.0% |
| FY2023 | Dec 31, 2023 | $64.61B | +65.9% |
| FY2022 | Dec 31, 2022 | $38.95B | +16.9% |
| FY2021 | Dec 31, 2021 | $33.31B | +1.0% |
| FY2020 | Dec 31, 2020 | $32.99B | +10.3% |
| FY2019 | Dec 31, 2019 | $29.90B | -11.9% |
| FY2018 | Dec 31, 2018 | $33.93B | -4.0% |
| FY2017 | Dec 31, 2017 | $35.34B | +2.2% |
| FY2016 | Dec 31, 2016 | $34.60B | +10.1% |
| FY2015 | Dec 31, 2015 | $31.43B | +2.3% |
| FY2014 | Dec 31, 2014 | $30.72B | -4.4% |
| FY2013 | Dec 31, 2013 | $32.13B | +33.7% |
| FY2012 | Dec 31, 2012 | $24.03B | +12.6% |
| FY2011 | Dec 31, 2011 | $21.34B | +96.3% |
| FY2010 | Dec 31, 2010 | $10.87B | +2.6% |
| FY2009 | Dec 31, 2009 | $10.60B | +158.9% |
| FY2008 | Dec 31, 2008 | $4.10B | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $54.01B | -1.1% |
| Q2 FY2026 | Jun 30, 2026 | $57.30B | +2.0% |
| Q1 FY2026 | Mar 31, 2026 | $57.32B | -0.1% |
| Q4 FY2025 | Dec 31, 2025 | $54.60B | -9.1% |
| Q3 FY2025 | Sep 30, 2025 | $54.59B | -9.6% |
| Q2 FY2025 | Jun 30, 2025 | $56.20B | -10.3% |
| Q1 FY2025 | Mar 31, 2025 | $57.38B | -10.4% |
| Q4 FY2024 | Dec 31, 2024 | $60.10B | -7.0% |
| Q3 FY2024 | Sep 30, 2024 | $60.40B | -0.1% |
| Q2 FY2024 | Jun 30, 2024 | $62.65B | +1.8% |
| Q1 FY2024 | Mar 31, 2024 | $64.02B | +3.9% |
| Q4 FY2023 | Dec 31, 2023 | $64.61B | +65.9% |
| Q3 FY2023 | Sep 30, 2023 | $60.47B | +56.2% |
| Q2 FY2023 | Jun 30, 2023 | $61.54B | +68.5% |
| Q1 FY2023 | Mar 31, 2023 | $61.60B | +67.1% |
| Q4 FY2022 | Dec 31, 2022 | $38.95B | +16.9% |
| Q3 FY2022 | Sep 30, 2022 | $38.70B | +3.0% |
| Q2 FY2022 | Jun 30, 2022 | $36.52B | +11.7% |
| Q1 FY2022 | Mar 31, 2022 | $36.85B | +11.7% |
| Q4 FY2021 | Dec 31, 2021 | $33.31B | -2.9% |
| Q3 FY2021 | Sep 30, 2021 | $37.58B | +9.8% |
| Q1 FY2021 | Mar 31, 2021 | $32.69B | +2.6% |
| Q4 FY2020 | Dec 31, 2020 | $32.99B | +10.3% |
| Q3 FY2020 | Sep 30, 2020 | $34.29B | +12.0% |
| Q2 FY2020 | Jun 30, 2020 | $34.22B | +3.6% |
| Q1 FY2020 | Mar 31, 2020 | $31.85B | -6.1% |
| Q4 FY2019 | Dec 31, 2019 | $29.90B | -13.1% |
| Q2 FY2019 | Jun 30, 2019 | $30.61B | -11.3% |
| Q1 FY2019 | Mar 31, 2019 | $33.02B | -7.1% |
| Q4 FY2018 | Dec 31, 2018 | $33.93B | -4.0% |
| Q3 FY2018 | Sep 30, 2018 | $34.43B | -3.8% |
| Q2 FY2018 | Jun 30, 2018 | $34.50B | -1.6% |
| Q1 FY2018 | Mar 31, 2018 | $35.54B | +4.3% |
| Q4 FY2017 | Dec 31, 2017 | $35.34B | +2.2% |
| Q3 FY2017 | Sep 30, 2017 | $35.78B | +1.3% |
| Q2 FY2017 | Jun 30, 2017 | $35.06B | +5.5% |
| Q1 FY2017 | Mar 31, 2017 | $34.09B | – |
| Q4 FY2016 | Dec 31, 2016 | $34.60B | – |
| Q3 FY2016 | Sep 30, 2016 | $35.32B | – |
| Q2 FY2016 | Jun 30, 2016 | $33.22B | – |
See a number that looks wrong?